Cover Image
市場調查報告書

Protagonist Therapeutics Inc.的產品平台分析

Protagonist Therapeutics Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321342
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Protagonist Therapeutics Inc.的產品平台分析 Protagonist Therapeutics Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 24 Pages
簡介

Protagonist Therapeutics Inc.是總公司位於美國的生物科技企業,正在開發二硫結合胜肽及抗體替代物質等治療中樞神經系統,腸胃系統,感染疾病,腫瘤,免疫,代謝系統疾病之治療藥用化合物。

本報告提供Protagonist Therapeutics Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,並彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

目錄

Protagonist Therapeutics Inc. 的基本資料

  • Protagonist Therapeutics Inc. 概要
  • 主要資訊
  • 企業資料

Protagonist Therapeutics Inc. :R&D概要

  • 主要的治療範圍

Protagonist Therapeutics Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Protagonist Therapeutics Inc. :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Protagonist Therapeutics Inc. :藥物簡介

  • Peptide Agonists of Hepcidin for Beta-Thalassemia and Juvenile Hemochromatosis
  • Synthetic Peptides to Antagonize Alpha-4 Beta-7 Integrin for IBD
  • Synthetic Peptides to Block Nav 1.7 Ion Channel for Pain
  • Synthetic Peptides To Inhibit Interleukin-6 for Inflammatory and Autoimmune Diseases
  • Synthetic Peptides to Target IL-23 and IL-23R for GI Disorders
  • Peptides for Irritable Bowel Syndrome and Inflammatory Bowel Disease
  • Synthetic Peptide for Diabetes, Cancer, Gastrointestinal Disorders and Infectious Disease
  • Synthetic Peptides for Gastrointestinal Disorders

Protagonist Therapeutics Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Protagonist Therapeutics Inc. :最新的開發平台資訊

Protagonist Therapeutics Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07529CDB

Summary

Global Markets Direct's, 'Protagonist Therapeutics Inc. - Product Pipeline Review - 2015', provides an overview of the Protagonist Therapeutics Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Protagonist Therapeutics Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Protagonist Therapeutics Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Protagonist Therapeutics Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Protagonist Therapeutics Inc.'s pipeline products

Reasons to buy

  • Evaluate Protagonist Therapeutics Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Protagonist Therapeutics Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Protagonist Therapeutics Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Protagonist Therapeutics Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Protagonist Therapeutics Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Protagonist Therapeutics Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Protagonist Therapeutics Inc. Snapshot
    • Protagonist Therapeutics Inc. Overview
    • Key Information
    • Key Facts
  • Protagonist Therapeutics Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Protagonist Therapeutics Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Protagonist Therapeutics Inc. - Pipeline Products Glance
    • Protagonist Therapeutics Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Protagonist Therapeutics Inc. - Drug Profiles
    • Peptide Agonists of Hepcidin for Beta-Thalassemia and Juvenile Hemochromatosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PTG-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Block Nav 1.7 Ion Channel for Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides To Inhibit Interleukin-6 for Crohn's Disease and Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Target IL-23R for Crohn's Disease and Ulcerative colitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Protagonist Therapeutics Inc. - Pipeline Analysis
    • Protagonist Therapeutics Inc. - Pipeline Products by Target
    • Protagonist Therapeutics Inc. - Pipeline Products by Route of Administration
    • Protagonist Therapeutics Inc. - Pipeline Products by Molecule Type
    • Protagonist Therapeutics Inc. - Pipeline Products by Mechanism of Action
  • Protagonist Therapeutics Inc. - Recent Pipeline Updates
  • Protagonist Therapeutics Inc. - Dormant Projects
  • Protagonist Therapeutics Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Protagonist Therapeutics Inc., Key Information
  • Protagonist Therapeutics Inc., Key Facts
  • Protagonist Therapeutics Inc. - Pipeline by Indication, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Stage of Development, 2015
  • Protagonist Therapeutics Inc. - Monotherapy Products in Pipeline, 2015
  • Protagonist Therapeutics Inc. - Preclinical, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Target, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Route of Administration, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Molecule Type, 2015
  • Protagonist Therapeutics Inc. - Pipeline Products by Mechanism of Action, 2015
  • Protagonist Therapeutics Inc. - Recent Pipeline Updates, 2015
  • Protagonist Therapeutics Inc. - Dormant Developmental Projects,2015
  • Protagonist Therapeutics Inc., Subsidiaries

List of Figures

  • Protagonist Therapeutics Inc. - Pipeline by Top 10 Indication, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Top 10 Target, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Protagonist Therapeutics Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top